It seems that there is a multitude of vaccines for typhoid, all of which seem to promise some type of benefit, treatment or prevention for those that are infected. In order to adequately rate these vaccines, it is necessary to have a basic understanding of what typhoid is, how it is spread and who is at risk. typhoid is caused by parasites called plagues, bacteria, virus and fungi. It is highly infectious and can cause complications such as arthritis and infection.
The pharmaceutical companies that market pharmaceuticals intended to provide treatment and prevention for typhoid fever rely heavily on their ability to produce vaccines and treatments for this highly contagious disease. There are two vaccines currently available, one each for men, women and children, which are also marketed as preventatives. These two vaccines, men Diphtheria and women typhoid, contain an agent called typhoid antigens. Men often receive one dose of Diphtheria-containing vaccination while women receive one dose of typhoid-preventing vaccine.
typhoid-immunizing vaccines and treatments are relatively safe and successful in preventing the onset of illness and making the remaining population healthy. The most commonly used medication is YMbe vaccination, which is part of the standard childhood vaccines. The second most commonly used is the typhoid-vax vaccine. Both shots are given at the same time and at least five weeks apart. Pertussis is a life-threatening condition, which occurs when the body’s immune system battles an untreated case of patellar chondromalacia (shin splints). Adequate diagnosis and prompt treatment with appropriate medications can prevent illness progression.
Several promising candidates have developed vaccines that are now in clinical trials. vaccine for typhoid, for example, has shown great potential for expanding the typhoid spectrum. Similarly, the vaccine for pertussis (chicken pox) is being studied. Both these vaccines to prevent infection by herpes simplex virus (HSV) in people who have little or no immunity to the disease. Clinical trials testing these drugs are currently underway.
Two vaccines have entered pre-clinical testing, and they are expected to enter first generation production very soon. These are the PC vaccines (Papp strain) and the live vaccine VZV. Both of these antigens have proven very effective in preventing fever blisters during acute typhoid infections. In a placebo-controlled trial, conducted in Brazil, 99% of those receiving VZV showed a high rate of improvement from a single day to 6 weeks. Also, after two months, there was a significant reduction in patients’ signs and symptoms, possibly because the body’s immunity began to build up slowly.
The risks of vaccine for typhoid must be weighed carefully with the benefits. There is some evidence, though not a great deal, that an attenuated vaccine might be less harmful than a live vaccine. Some researchers think that this risk occurs because an attenuated vaccine produces a milder form of the illness; it also produces a slower speedier recovery. Still, this has not been firmly established.